Ranolazine and Microvascular Angina by PET in the Emergency Department

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of Ranolazine for the treatment chest pain from disease of small vessels of the heart also known as 'microvascular angina'.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: Gilead Sciences
• Treatments: Ranolazine

Criteria

Inclusion Criteria:

• Patients admitted to the Yale ED CPC

• ≥ 30 years age

• chest pain or angina equivalent as their chief complaint within 24 hours of enrollment

• Coronary Flow Reserve(CFR) <2.5 on PET scan in the ED.

Exclusion Criteria:

• Acute coronary syndrome

• Prior evidence of obstructive heart disease (history of Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass Grafting (CABG) or calcium score > 10 on PET scan)

• Resting blood pressure of systolic >180/110 mm Hg or <100/40

• known cardiomyopathy or heart failure

• currently on dialysis

• creatinine clearance <30 ml/min

• liver cirrhosis

• significant aortic stenosis (murmur on exam)

• active use of cocaine or amphetamine

• current use of potent CYP3A4 inducers or inhibitors (such as ketoconazole, clarithromycin, HIV protease inhibitors)

• baseline QTc > 580 msec

• use of drugs that prolong QTc (Haldol, erythromycin)

• pregnancy

• inability to read or understand English

• suffering from a condition that precludes interview (i.e. cognitive or communication impairment).